PozLab is a contract development and manufacturing organization in the pharmaceutical industry offering expert drug product development services and small pilot plant capabilities, including analytical, formulation, and process development competencies, followed by microbiological testing. With a GMP license for the manufacture of medical and investigational products, PozLab is committed to providing comprehensive and innovative services of the highest quality in the pharmaceutical area. Since May 2024, PozLab has been a part of the Selvita Group. This strategic move has likely further enhanced PozLab's capabilities and offerings within the pharmaceutical industry, solidifying its position as a key player in the market. Despite the absence of specific details about recent investments or investors, PozLab's alignment with such a prominent group suggests a significant level of stability and potential for future growth. Its focus on essential services and connection to a larger network position PozLab as a promising player in the pharmaceutical development and manufacturing landscape.
There is no investment information
No recent news or press coverage available for PozLab.